Commercialization of cell therapies — biopreservation’s make or break impact: an interview with Mike Rice

Written by Freya Leask
Biobanking Industry developments Interviews Manufacturing & scale-up Preclinical research Spotlight on commercialization and translation
Close up of an endangered species genetic bank, samples stored for future resurrection, the preservation units a frosty blur in the secure facility, sharpen with copy space

Mike Rice, CEO of NASDAQ traded BioLifeSolutions (WA, USA) explains the importance of biopreservation in commercializing regenerative medicine therapies and why funding for new cell-based therapies remains high.

In this interview, Mike Rice, CEO of NASDAQ traded BioLifeSolutions (WA, USA) explains why effective biopreservation is critical for commercialization of regenerative medicine therapies, and why private, corporate and public funding for new cell-based therapies remains high.